Acutus Medical, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Takeo Mukai
- Full Time Employees
- 85
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 2210 Faraday Avenue Carlsbad CA United States of America 92008
- IPO Date
- Aug 6, 2020
- CIK
- 0001522860
- Website
- acutusmedical.com
- Similar Companies
- Business
- Acutus Medical, Inc. is a medical technology company specializing in the development and manufacturing of innovative electrophysiology (EP) products and solutions designed to improve the diagnosis and treatment of cardiac arrhythmias. The company’s core product portfolio includes the AcQMap 3D Imaging and Mapping System, a unique noncontact mapping technology enabling real-time full chamber global activation mapping for catheter-based cardiac arrhythmia treatments; AcQCross Transseptal Access System; AcQGuide; and related catheter-based electrophysiology tools and accessories. These products serve electrophysiology labs and cardiology centers globally, providing advanced cardiac mapping, ablation, and diagnostic solutions. Founded in 2008 and headquartered in Carlsbad, California, Acutus Medical formerly operated with a broader focus on electrophysiology mapping and ablation systems. However, in 2023 through early 2024, the company initiated a strategic realignment and corporate restructuring to refocus its business exclusively on contract manufacturing, specifically supporting the production and distribution of left-heart access devices in partnership with Medtronic. This shift involved divesting its mapping and ablation business, including the November 2023 substantial workforce reduction of approximately 65%, and a strategic exit from electrophysiology system operations. The company transferred core electrophysiology mapping assets, including AcQMap platform intellectual property and equipment, to EnChannel Medical in mid-2025. Since the restructuring, Acutus Medical operates principally as a contract manufacturing entity for Medtronic’s left-heart access product line. The company’s recent operational changes include settling a significant credit agreement amendment with Deerfield Management in early 2025 and ongoing commitments to fulfill obligations under the Medtronic contract manufacturing agreement, supporting procedures involving left-heart access devices. The strategic refocus aims at stabilizing cash flows and reducing operational costs, transitioning Acutus Medical into a leaner organization focused on manufacturing services within the medical device sector. Acutus Medical’s geographic operations primarily cover the United States, while its products and services have been deployed in various global markets through its electrophysiology systems and manufacturing contracts. Acutus Medical is positioned within the cardiac arrhythmia care industry, targeting electrophysiologists, cardiac surgeons, and medical institutions specializing in arrhythmia treatment. Its historical contributions center on developing differentiated electrophysiology tools and imaging technologies, while its current emphasis is on manufacturing excellence and operational efficiency as a contract manufacturing partner in the cardiac device supply chain. This description integrates Acutus Medical’s product offerings and significant recent organizational and strategic changes highlighting its transition from a technology platform provider to a focused contract manufacturing company supporting Medtronic, reflecting the latest developments through 2025.
Reviewing T2 Biosystems (NASDAQ:TTOO) & Acutus Medical (NASDAQ:AFIB)
Comparing Carmell (NASDAQ:CTCX) and Acutus Medical (NASDAQ:AFIB)
Acutus Medical (NASDAQ:AFIB) versus Assure (NASDAQ:IONM) Head to Head Survey
Financial Analysis: SANUWAVE Health (OTCMKTS:SNWV) vs. Acutus Medical (NASDAQ:AFIB)
Acutus Medical Reports Full Year 2024 Financial Results
Acutus Medical Announces Operational Downsizing
Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results
Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results
Acutus Medical Reports First Quarter 2024 Financial Results
Why Is Acutus Medical (AFIB) Stock Down 41% Today?
Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results
Top 4 Health Care Stocks That Could Blast Off This Quarter - Acutus Medical (NASDAQ:AFIB), Becton Dickinson (NYSE:BDX)
Acutus Medical to Cancel Third Quarter 2023 Conference Call
Acutus Medical Reports Third Quarter 2023 Financial Results
Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring
Acutus Medical to Announce Third Quarter 2023 Financial Results
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acutus Medical, Inc. (AFIB) Q2 2023 Earnings Call Transcript
Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates